House Oversight Panel's Investigation Of FDA Puerto Rico Office Previews Focus On Agency Operations Under GOP
This article was originally published in The Pink Sheet Daily
Executive Summary
Reps. Towns and Issa suggest office may lack sufficient staff to adequately monitor pharmaceutical manufacturers on the island.
You may also be interested in...
FDA’s Congressional Relations, Internal Structure May Change With Sharfstein’s Departure
The departure of Principal Deputy Commissioner Joshua Sharfstein provides FDA an opportunity to take stock of its relationship with the new Congress and to re-evaluate its own organizational structure.
FDA’s Congressional Relations, Internal Structure May Change With Sharfstein’s Departure
The departure of Principal Deputy Commissioner Joshua Sharfstein provides FDA an opportunity to take stock of its relationship with the new Congress and to re-evaluate its own organizational structure.
GMP Violations At GSK's Former Puerto Rico Plant Are Basis Of $750 Million DoJ Settlement
In the first False Claims Act case alleging cGMP violations the government cites microbial contamination, split tablets and product mix-ups.